Skip to main content
Erschienen in:

31.03.2021 | original article

Relationship of dehydroepiandrosterone sulfate levels with atherosclerosis in patients with subclinical hypothyroidism

verfasst von: Ass. Prof. Gulsum Gonulalan, MD, Yusuf Tanrıkulu, MD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 1-2/2022

Einloggen, um Zugang zu erhalten

Summary

Background

Subclinical hypothyroidism is related with increased risk of cardiovascular diseases. The decreased levels of dehydroepiandrosterone sulphate (DHEA-S) are associated with hyperlipidemia, atherosclerosis and obesity. The lower levels of DHEA‑S might be an important factor in development of atherosclerosis in subclinical hypothyroidism.

Methods

A total of 126 patients (62 with subclinical hypothyroidism and 64 healthy individuals) were included in this prospectively designed study between January 2017 and December 2019. All individuals were evaluated according to DHEA‑S levels, carotid intima media thickness (CIMT) and anthropometric measurements. Blood samples were obtained from patients after 8 h fasting. The groups were statistically compared.

Results

The mean ages of control group and patients with subclinical hypothyroidism were 36.9 ± 11.0 years and 39.6 ± 11.0 years, respectively (p = 0.165). The mean waist circumferences in controls and patients were 89 ± 10.7 cm and 91.3 ± 11.1 cm, respectively (p < 0.001). The DHEA‑S levels were 131.04 ± 96.02 µg/dl in patients, and these levels were significantly decreased in patients with subclinical hypothyroidism (p = 0.024). The levels of DHEA‑S were found to be negatively correlated with CIMT (p < 0.001, c = 0.406).

Conclusions

The early detection of cardiac and metabolic dysfunctions in subclinical hypothyroidism is important to avoid complications. We found a negative correlation between DHEA‑S levels and metabolic and cardiovascular risk factors in subclinical hypothyroidism. We believe that our results would attract more attention to the studies investigating relationships between DHEA‑S levels and cardiovascular complications of subclinical hypothyroidism.
Literatur
1.
Zurück zum Zitat Cooper DS. Clinical practice subclinical hypothyroidism. N Eng J Med. 2001;345(4):260–5.CrossRef Cooper DS. Clinical practice subclinical hypothyroidism. N Eng J Med. 2001;345(4):260–5.CrossRef
2.
Zurück zum Zitat Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160(4):526–34.CrossRef Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160(4):526–34.CrossRef
3.
Zurück zum Zitat Saif A, Mousa S, Assem M, Tharwat N, Abdelhamid A. Endothelial dysfunction and the risk of atherosclerosisin overt and subclinical hypothyroidism. Endocr Connect. 2018;7(10):1075–80.CrossRef Saif A, Mousa S, Assem M, Tharwat N, Abdelhamid A. Endothelial dysfunction and the risk of atherosclerosisin overt and subclinical hypothyroidism. Endocr Connect. 2018;7(10):1075–80.CrossRef
4.
Zurück zum Zitat Perrini S, Laviola L, Natalicchio A, Giorgino F. Associated hormonal declines in aging: DHEA‑S. J Endocrinol Invest. 2005;28(3):85–93.PubMed Perrini S, Laviola L, Natalicchio A, Giorgino F. Associated hormonal declines in aging: DHEA‑S. J Endocrinol Invest. 2005;28(3):85–93.PubMed
5.
Zurück zum Zitat Barrett-Connor E, Khaw KT, Yen SS. Aprospective study of dehydroepiandrosteronesulfate, mortality and cardiovascular disease. N Engl J Med. 1986;315(24):1519–24.CrossRef Barrett-Connor E, Khaw KT, Yen SS. Aprospective study of dehydroepiandrosteronesulfate, mortality and cardiovascular disease. N Engl J Med. 1986;315(24):1519–24.CrossRef
6.
Zurück zum Zitat Cappola AR, O’Meara ES, Guo W, Bartz TM, Fried LP, Newman AB. Trajectories of dehydroepiandrosteronesulfate predict mortality in older adults: the cardiovascular health study. J Gerontol A Biol Sci Med Sci. 2009;64(12):1268–74.CrossRef Cappola AR, O’Meara ES, Guo W, Bartz TM, Fried LP, Newman AB. Trajectories of dehydroepiandrosteronesulfate predict mortality in older adults: the cardiovascular health study. J Gerontol A Biol Sci Med Sci. 2009;64(12):1268–74.CrossRef
7.
Zurück zum Zitat Page JH, Ma J, Rexrode KM, Rifai N, Manson JE, Hankinson SE. Plasma dehydroepiandrosterone and risk of myocardial infarction in women. Clin Chem. 2008;54(7):1190–6.CrossRef Page JH, Ma J, Rexrode KM, Rifai N, Manson JE, Hankinson SE. Plasma dehydroepiandrosterone and risk of myocardial infarction in women. Clin Chem. 2008;54(7):1190–6.CrossRef
8.
Zurück zum Zitat Shufelt C, Bretsky P, Almeida CM, et al. DHEA‑S levels and cardiovascular disease mortality in postmenopausal women: results from the National Institutes of Health-National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women’s Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol Metab. 2010;95(11):4985–92.CrossRef Shufelt C, Bretsky P, Almeida CM, et al. DHEA‑S levels and cardiovascular disease mortality in postmenopausal women: results from the National Institutes of Health-National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women’s Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol Metab. 2010;95(11):4985–92.CrossRef
9.
Zurück zum Zitat Kahonen MH, Tilvis RS, Jolkkonen J, Pitkälä K, Härkönen M. Predictors and clinical significance of declining plasma dehydroepiandrosteronesulfate in old age. Aging. 2000;12(4):308–14.PubMed Kahonen MH, Tilvis RS, Jolkkonen J, Pitkälä K, Härkönen M. Predictors and clinical significance of declining plasma dehydroepiandrosteronesulfate in old age. Aging. 2000;12(4):308–14.PubMed
10.
Zurück zum Zitat Legrain S, Girard L. Pharmacology and therapeutic effect of dehydroepiandrosterone in older subjects. Drugs Aging. 2003;20(13):949–67.CrossRef Legrain S, Girard L. Pharmacology and therapeutic effect of dehydroepiandrosterone in older subjects. Drugs Aging. 2003;20(13):949–67.CrossRef
11.
Zurück zum Zitat Barrett-Connor E, Ferrara A. Dehydroepiandrosterone, dehydroepiandrosterone sulfate, obesity, waist-hip ratio, and noninsulin-dependent diabetes in postmenopausal women: the Rancho Bernardo Study. J Clin Endocrinol Metab. 1996;81(1):59–64.PubMed Barrett-Connor E, Ferrara A. Dehydroepiandrosterone, dehydroepiandrosterone sulfate, obesity, waist-hip ratio, and noninsulin-dependent diabetes in postmenopausal women: the Rancho Bernardo Study. J Clin Endocrinol Metab. 1996;81(1):59–64.PubMed
12.
Zurück zum Zitat Tsigos C, Hainer V, Basdevant A, et al. Management of obesity in adults: European clinical practice guidelines. Obes Facts. 2008;1(2):106–16.CrossRef Tsigos C, Hainer V, Basdevant A, et al. Management of obesity in adults: European clinical practice guidelines. Obes Facts. 2008;1(2):106–16.CrossRef
13.
Zurück zum Zitat World Health Organization. Waist circumference and waist-hipratio. Report of a WHO expert consultation. December 8–11. Geneva: WHO; 2008. World Health Organization. Waist circumference and waist-hipratio. Report of a WHO expert consultation. December 8–11. Geneva: WHO; 2008.
14.
Zurück zum Zitat Imga NN, Topcuoglu C, Berker D, Turhan T. Serum amyloid A, paraoxonase-I activity and apolipoprotein concentrations as biomarkers of subclinical atherosclerosis risk in adrenal incidentaloma patients. Arch Med Res. 2018;49(3):182–90.CrossRef Imga NN, Topcuoglu C, Berker D, Turhan T. Serum amyloid A, paraoxonase-I activity and apolipoprotein concentrations as biomarkers of subclinical atherosclerosis risk in adrenal incidentaloma patients. Arch Med Res. 2018;49(3):182–90.CrossRef
15.
Zurück zum Zitat Ojamaa K, Sabet A, Kenessey A, Shenoy R, Klein I. Regulation of rat cardiac gene expression by thyroid hormone is rapidandchamberspecific. Endocrinology. 1999;140(7):3170–6.CrossRef Ojamaa K, Sabet A, Kenessey A, Shenoy R, Klein I. Regulation of rat cardiac gene expression by thyroid hormone is rapidandchamberspecific. Endocrinology. 1999;140(7):3170–6.CrossRef
16.
Zurück zum Zitat Cerbone M, Capalbo D, Wasniewska M, et al. Cardiovascular risk factors in children with long-standing untreated idiopathic subclinical hypothyroidism. J Clin Endocrinol Metab. 2014;99(8):2697–703.CrossRef Cerbone M, Capalbo D, Wasniewska M, et al. Cardiovascular risk factors in children with long-standing untreated idiopathic subclinical hypothyroidism. J Clin Endocrinol Metab. 2014;99(8):2697–703.CrossRef
17.
Zurück zum Zitat Biondi B. Thyroid and obesity: an intriguing relationship. J Clin Endocrinol Metab. 2010;95(8):3614–7.CrossRef Biondi B. Thyroid and obesity: an intriguing relationship. J Clin Endocrinol Metab. 2010;95(8):3614–7.CrossRef
18.
Zurück zum Zitat Asvold BO, Bjoro T, Vatten LJ. Association of serum TSH with high body mass differs between smokers and nonsmokers. J Clin Endocrinol Metab. 2009;94(12):5023–7.CrossRef Asvold BO, Bjoro T, Vatten LJ. Association of serum TSH with high body mass differs between smokers and nonsmokers. J Clin Endocrinol Metab. 2009;94(12):5023–7.CrossRef
19.
Zurück zum Zitat Mousa U, Bozkuş Y, Kut A, Demir CC, Tutuncu NB. Fat distribution and metabolic profile in subjects with hashimoto’s thyroiditis. Acta Endocrinol. 2018;14(1):105–12. Mousa U, Bozkuş Y, Kut A, Demir CC, Tutuncu NB. Fat distribution and metabolic profile in subjects with hashimoto’s thyroiditis. Acta Endocrinol. 2018;14(1):105–12.
20.
Zurück zum Zitat Yasar HY, Topaloglu O, Demirpence M, Ceyhan BO, Guclu F. Is subclinical hypothyroidism in patients with polycystic ovary syndrome associated with BMI? Acta Endocrinol. 2016;12(4):431–6. Yasar HY, Topaloglu O, Demirpence M, Ceyhan BO, Guclu F. Is subclinical hypothyroidism in patients with polycystic ovary syndrome associated with BMI? Acta Endocrinol. 2016;12(4):431–6.
21.
Zurück zum Zitat Rothwell PM. The Interrelation between carotid, femoral and coronary artery disease. Eur Heart J. 2001;22(1):11–4.CrossRef Rothwell PM. The Interrelation between carotid, femoral and coronary artery disease. Eur Heart J. 2001;22(1):11–4.CrossRef
22.
Zurück zum Zitat Mukherjee D, Yadav JS. Carotid artery intimal-medial thickness: indicator of atherosclerotic burden and responseto risk factormodification. Am Heart J. 2002;144(5):753–9.CrossRef Mukherjee D, Yadav JS. Carotid artery intimal-medial thickness: indicator of atherosclerotic burden and responseto risk factormodification. Am Heart J. 2002;144(5):753–9.CrossRef
23.
Zurück zum Zitat Dhatariya KK, Nair KS. Dehydroepiandrosterone: is there a role forreplacement? Mayo Clin Proc. 2003;78(10):1257–1253.CrossRef Dhatariya KK, Nair KS. Dehydroepiandrosterone: is there a role forreplacement? Mayo Clin Proc. 2003;78(10):1257–1253.CrossRef
24.
Zurück zum Zitat Hernandez-Morante JJ, Milagro F, Gabaldon JA, Martinez JA, Zamora S, Garaulet M. Effect of DHEA-sulfate on adiponectin gene expression in adipose tissue from different fat depots in morbidly obese humans. Eur J Endocrinol. 2006;155(4):593–4.CrossRef Hernandez-Morante JJ, Milagro F, Gabaldon JA, Martinez JA, Zamora S, Garaulet M. Effect of DHEA-sulfate on adiponectin gene expression in adipose tissue from different fat depots in morbidly obese humans. Eur J Endocrinol. 2006;155(4):593–4.CrossRef
25.
Zurück zum Zitat Wang YD, Tao MF, Cheng WW, Liu XH, Wan XP, Cui K. Dehydroepiandrosterone indirectly inhibits human osteoclastic resorption via activating osteoblastic viability by the MAPK pathway. Chin Med J. 2012;125(7):1230–5.PubMed Wang YD, Tao MF, Cheng WW, Liu XH, Wan XP, Cui K. Dehydroepiandrosterone indirectly inhibits human osteoclastic resorption via activating osteoblastic viability by the MAPK pathway. Chin Med J. 2012;125(7):1230–5.PubMed
26.
Zurück zum Zitat Benelli C, Michel O, Michel R. Effect of thyroidectomy on pregnenolone and progesterone biosynthesis in rat adrenal. J Steroid Biochem. 1982;16(6):749–54.CrossRef Benelli C, Michel O, Michel R. Effect of thyroidectomy on pregnenolone and progesterone biosynthesis in rat adrenal. J Steroid Biochem. 1982;16(6):749–54.CrossRef
27.
Zurück zum Zitat Ohlsson C, Labrie F, Barrett-Connor E, et al. Low serum levels of dehydroepiandrosteronesulfatepredictall-causeandcardiovascularmortality in elderlySwedish men. J Clin Endocrinol Metab. 2010;95(9):4406–14.CrossRef Ohlsson C, Labrie F, Barrett-Connor E, et al. Low serum levels of dehydroepiandrosteronesulfatepredictall-causeandcardiovascularmortality in elderlySwedish men. J Clin Endocrinol Metab. 2010;95(9):4406–14.CrossRef
28.
Zurück zum Zitat Jimenez MC, Sun Q, Schurks M, et al. Low dehydroepiandrosteronesulfate is associated with increased risk of ischemic stroke among women. Stroke. 2013;44(7):1784–9.CrossRef Jimenez MC, Sun Q, Schurks M, et al. Low dehydroepiandrosteronesulfate is associated with increased risk of ischemic stroke among women. Stroke. 2013;44(7):1784–9.CrossRef
29.
Zurück zum Zitat Browne ES, Porter JR, Correa G, Abadie J, Svec F. Dehydroepiandrosterone regulation of the hepatic glucocorticoid receptor in the Zucker rat. The obesity research program. J Steroid Biochem Mol Biol. 1993;45(6):517–24.CrossRef Browne ES, Porter JR, Correa G, Abadie J, Svec F. Dehydroepiandrosterone regulation of the hepatic glucocorticoid receptor in the Zucker rat. The obesity research program. J Steroid Biochem Mol Biol. 1993;45(6):517–24.CrossRef
30.
Zurück zum Zitat Wolf OT, Kirschbaum C. Actions of dehydroepiandrosterone and its sulfate in the central nervous system: effects on cognition and emotion in animals and humans. Brain Res Rev. 1999;30(3):264–98.CrossRef Wolf OT, Kirschbaum C. Actions of dehydroepiandrosterone and its sulfate in the central nervous system: effects on cognition and emotion in animals and humans. Brain Res Rev. 1999;30(3):264–98.CrossRef
31.
Zurück zum Zitat Nilsson T, Mellbring G, Damber JE. Relationships between tissue plasmino gen activator, steroid hormones, and deep vein thrombosis. Acta Chir Scand. 1985;151(6):515–9.PubMed Nilsson T, Mellbring G, Damber JE. Relationships between tissue plasmino gen activator, steroid hormones, and deep vein thrombosis. Acta Chir Scand. 1985;151(6):515–9.PubMed
32.
Zurück zum Zitat Beer NA, Jakubowicz DJ, Matt DW, Beer RM, Nestler JE. Dehydroepiandrosterone reduces plasma plasminogen activator inhibitor type 1 and tissue plasminogen activator antigen in men. Am J Med Sci. 1996;311(5):205–10.CrossRef Beer NA, Jakubowicz DJ, Matt DW, Beer RM, Nestler JE. Dehydroepiandrosterone reduces plasma plasminogen activator inhibitor type 1 and tissue plasminogen activator antigen in men. Am J Med Sci. 1996;311(5):205–10.CrossRef
33.
Zurück zum Zitat Gordon GB, Newitt JA, Shantz LM, Weng DE, Talalay P. Inhibition of theconversion of 3T3 fibroblastclonesto adipocytes by dehydroepiandrosterone and related anticarcinogenic steroids. Cancer Res. 1986;46(7):3389–95.PubMed Gordon GB, Newitt JA, Shantz LM, Weng DE, Talalay P. Inhibition of theconversion of 3T3 fibroblastclonesto adipocytes by dehydroepiandrosterone and related anticarcinogenic steroids. Cancer Res. 1986;46(7):3389–95.PubMed
34.
Zurück zum Zitat Akyürek N, Atabek ME, Eklioglu BS, Alp H. Is there a relationship between cardiovascular risk factors and dehydroepiandrosteronesulfate levels in childhood obesity? J Pediatr Endocrinol Metab. 2015;28(5–6):545–50.PubMed Akyürek N, Atabek ME, Eklioglu BS, Alp H. Is there a relationship between cardiovascular risk factors and dehydroepiandrosteronesulfate levels in childhood obesity? J Pediatr Endocrinol Metab. 2015;28(5–6):545–50.PubMed
Metadaten
Titel
Relationship of dehydroepiandrosterone sulfate levels with atherosclerosis in patients with subclinical hypothyroidism
verfasst von
Ass. Prof. Gulsum Gonulalan, MD
Yusuf Tanrıkulu, MD
Publikationsdatum
31.03.2021
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 1-2/2022
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-021-01844-9